Finasteride-obl tab n / 5mg film about 30 pc

Description

Composition
Active substance:
1 tablet contains: Finasteride – 5.0 mg.
Excipients:
Lactose monohydrate – 79.0 mg calcium hydrogen phosphate dihydrate – 21.0 mg Croscarmellose sodium – 0.7 mg Sodium dodecyl sulfate – 1.2 mg Microcrystalline cellulose – 20.0 mg, giprolozaa (hydroxypropyl) – 1.8 mg magnesium stearate – 1.3 mg of the shell: 1.6mg copovidone, giproloza (hydroxypropyl cellulose) 1.6 mg talc 0.6 mg titanium dioxide 1.198 mg, 0.002 mg azorubin dye.
Description:
Tablets, film-coated, from light pink to pink, round, biconvex shape. The cross section shows two layers, the inner layer of white or almost white color.
Product form:
Coated tablets 5 mg. At 7, 10, 14, 15, 20 or 30 tablets in blisters. 1, 2,3 or 4 outline package together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to finasteride and other components of the drug, prostate cancer, urinary tract obstruction, childhood.
With care – abnormal liver function.
Indications
Finasteride shown in benign prostatic hyperplasia (to reduce the size of the prostate, of increasing the maximum speed of the flow of urine and reduce the symptoms associated with hyperplasia, reduce the risk of acute urinary retention and the associated probability of surgical intervention.
Interaction with other drugs
Not detected clinically significant interactions with other drugs.
Overdose
Currently, the cases of drug overdose Finasteride has not been reported.
pharmachologic effect
Pharmacological group:
5-alpha reductase inhibitor.
Pharmacological properties:
Finasteride, a synthetic 4-azasteroid compound, a specific and competitive inhibitor of steroid 5-alpha-reductase – intracellular enzyme that converts testosterone to the active androgen DHT-5. The growth of prostate tissue and development of benign prostatic hyperplasia caused by conversion of testosterone to dihydrotestosterone in the prostate cells. Under the influence of the drug is a significant reduction in the concentration digidrosterona in blood plasma and in breast tissue. Finasteride does not bind to androgen receptors.
As a result of the drug decreases the size of the prostate, it reduced the severity of symptoms associated with benign prostatic hyperplasia. The drug has no effect on the plasma lipid concentration as well as the content of cortisol in the blood plasma, estradiol, prolactin, thyroid stimulating hormone, thyroxine.
Pharmacokinetics:
Absorption and distribution: After taking the drug inside finasteride is rapidly absorbed from the gastrointestinal tract. The bioavailability is about 80% and is independent of food intake. Maximum plasma concentration is achieved 1-2 hours after ingestion of the drug. Communication with the plasma proteins is approximately 90%.
Metabolism and excretion: Finasteride is metabolized by the liver and excreted as metabolites in the urine and feces. the half-life of the drug in patients older than 60 years sostalyaet 6 hours in patients older than 70 years can be extended up to 8 hours.
Conditions of supply of pharmacies
Prescription.
special instructions
Prior to treatment is necessary to eliminate the disease, which can simulate benign prostatic hyperplasia such as infectious prostatitis, prostate cancer, urethral stricture, hypotension, urinary bladder, and a number of changes in the urinary tract, resulting in certain diseases of the nervous system.
Since the application of finasteride observed reduction of prostate-specific antigen (by 41% and 48% respectively at 6 and 12 months after initiation of therapy) periodically during therapy is necessary to conduct examination to exclude patients have prostate cancer.
Women of childbearing age and pregnant women should avoid contact with crushed tablets of Finasteride drug as ability of the drug to inhibit the conversion of testosterone to dihydrotestosterone can cause impaired development of genital organs of male fetus. Finasteride coated tablets and film-coated under normal handling, unless they are ground into powder or n compromised their integrity, the contact with the active material removed.
Storage conditions
In a dry, light and reach of children at a temperature not higher than 25C.
Dosing and Administration
Finasteride taken orally without food 1 tablet (5 mg) per day for 6-7 months
Side effects: Allergic reactions, gynecomastia, breast tenderness, impotence, decreased libido and ejaculate volume reduction. The frequency of side effects, does not exceed 3-4% and decreases during the treatment. In some cases, noted the concentration increase of luteinizing hormone and follicle-stimulating hormone and testosterone by approximately 10%, however, these indicators remained within normal limits.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist